Skip to main content
Medical Reference · Condition Monograph

Metabolic Dysfunction-Associated Fatty Liver Disease

대사이상관련지방간질환

Metabolic dysfunction-associated fatty liver disease was previously more widely known as "nonalcoholic fatty liver disease."

History

Metabolic dysfunction-associated fatty liver disease was previously more widely known as "nonalcoholic fatty liver disease." The former name emphasized that "fatty liver develops even without drinking alcohol," but it became increasingly clear that problems related to the body's energy metabolism, such as obesity, diabetes, hyperlipidemia, and hypertension, are actually at the center. Therefore, to reveal the core of the disease more accurately, the terminology was reorganized by first establishing the broad category of "liver disease in which fat accumulates in the liver" and then separately grouping the cases accompanied by metabolic dysfunction.

This change was not simply a change of name. First, by putting "poor metabolic health" at the forefront rather than the condition of "not drinking alcohol," the focus of diagnosis and counseling shifted to managing lifestyle and metabolic diseases. Second, it came to reflect the reality that fatty liver can exist together with other liver diseases. For example, when alcohol consumption is above a certain level, the case can be classified and explained separately as a category in which metabolic dysfunction and alcohol factors act together.

In addition, fatty liver was easy to neglect because of the perception that "fatty liver usually has no symptoms and is common," but in the process of revising the terminology, the view was emphasized that it is "not just a liver problem but a chronic disease linked to systemic risks such as cardiovascular disease and kidney disease." Recent studies have reported that even when the new classification criteria are applied, most people who were previously grouped under nonalcoholic fatty liver disease are included in the same category, so the transition is possible in clinical practice without major confusion.

Causes

The core cause of metabolic dysfunction-associated fatty liver disease is "a situation in which the energy entering the liver (mainly fat and sugar) exceeds the amount the liver can process." In this situation, the liver tries to store the excess energy in the form of fat, and as a result, fat accumulates inside the liver cells. It is difficult to pin the cause down to one factor; lifestyle, body weight, hormones, genetic predisposition, sleep and stress, and the gut environment are intertwined and act together.

The most common starting point is excessive calorie intake and insufficient activity. In particular, frequently consuming rapidly absorbed carbohydrates, such as sugary drinks or snacks and processed foods, increases the swings in blood sugar and insulin and can excessively stimulate the "process of making new fat" in the liver. Even without obesity, fatty liver can develop if there is a large amount of abdominal fat (visceral fat), low muscle mass, and insufficient activity. Metabolic diseases are also an important causal axis. Type 2 diabetes or prediabetes, dyslipidemia, and hypertension often occur together, and this combination itself greatly raises the risk of fatty liver.

It is more realistic to view alcohol not as "an item to be excluded as a cause" but as "a factor that can act together." When alcohol consumption is above a certain amount, liver damage and fibrosis can progress more rapidly, so it must be checked in classification and counseling. In addition, when conditions such as hypothyroidism, polycystic ovary syndrome, and sleep apnea are present, the risk of fatty liver and the risk of progression can become greater.

Genetic Epidemiology

Metabolic dysfunction-associated fatty liver disease is one of the representative common diseases in which family history and genetic predisposition play a role. Genetic differences partly explain why, even with the same lifestyle, some people develop fatty liver easily while others develop it relatively less. However, heredity is closer to "susceptibility" than to "destiny." In other words, it is more accurate to understand it as a factor that slightly increases the likelihood of fat accumulating more readily or worsening more quickly in the same environment.

Several gene variants are known to be associated with the development and severity of fatty liver and the progression of fibrosis. In particular, gene variants involved in the processes of handling and storing fat in the liver are frequently mentioned. With these variants, even at the same body weight and the same blood sugar status, fat may accumulate more readily in the liver, or inflammation and fibrosis may progress more easily. Differences by ethnicity and race are also observed, and these are the result not only of genetic background but also of environmental factors acting together, such as dietary composition, degree of urbanization, access to medical care, and body type.

Recent research emphasizes that it is practical to use "family history as a warning sign" while, in actual clinical practice, prioritizing metabolic indicators such as body weight, waist circumference, blood sugar, blood pressure, and blood lipids, along with assessment of the risk of liver fibrosis.

General Epidemiology

Metabolic dysfunction-associated fatty liver disease is regarded as the most common category of chronic liver disease worldwide. A considerable proportion of the adult population has some degree of fat accumulation in the liver, and it is found much more commonly in groups with obesity or type 2 diabetes. Conversely, it also occurs at a certain rate in people whose body weight is within the normal range; such cases are called "lean fatty liver," and it is rare for their metabolic indicators to be completely normal.

Prevalence varies greatly by region and population group. Westernization of diet, decreased activity, increased consumption of processed foods, lack of sleep, and increased stress are changes commonly observed in many countries, and these changes move in the same direction as the increase in fatty liver. Recent studies show that prevalence has clearly increased over the past several decades, and the increase among adolescents and young adults in particular has been raised as a concern.

What is clinically important is the fact that "even though fatty liver is common, not everyone progresses to cirrhosis or liver cancer." Most people live without major problems, but in some, liver inflammation and fibrosis progress and can lead to cirrhosis and liver cancer. Because people with fatty liver tend to have a higher risk of cardiovascular disease as well, it is advantageous to set the goal of management not as "only normalizing liver enzyme levels" but as "improving overall metabolic health."

Pathogenesis

The pathogenesis of metabolic dysfunction-associated fatty liver disease is easy to understand when divided into "the process by which fat accumulates in the liver" and "the process by which that fat leads to inflammation and scarring (fibrosis)." In the first stage, the liver receives fat through three routes. First, fat from food flows into the liver. Second, fatty acids are released into the blood from the body's adipose tissue (especially visceral fat) and enter the liver. Third, sugar (especially excess carbohydrates) is converted into new fat in the liver. When metabolic dysfunction is present, these three routes tend to become overactive at the same time.

Insulin resistance is the central axis. When insulin does not work well, fatty acids escape more easily from adipose tissue, and in the liver, the process of making new fat stays switched on. The second stage is the transition from "simple fat accumulation" to "inflammation and injury." When byproducts of fat metabolism, certain fat components, and oxidative stress increase, liver cells are damaged and an inflammatory response is activated. Immune cells become involved, and when the hepatic stellate cells are activated, collagen accumulates and fibrosis progresses.

Changes in the gut microbiota are also cited as part of the mechanism. When the intestinal barrier weakens or the composition of microorganisms changes, more inflammatory signals can be transmitted to the liver, which intensifies liver inflammation. In recent research, there has been a stronger trend toward explaining why the rate of progression and response vary even among the same "fatty liver" with a "multiple-hit model in which several pathways act at the same time."

Symptoms

In most cases, metabolic dysfunction-associated fatty liver disease has no symptoms in the early stage. Therefore, it is common for people to live without knowing that fat has accumulated in their liver until liver enzyme levels come back high at a health checkup or it is discovered incidentally on an abdominal ultrasound or computed tomography scan taken for another reason. Even when symptoms occur, they are nonspecific. Symptoms such as fatigue, lethargy, and indigestion are common, but it is difficult to suspect fatty liver from these alone. Some people feel heaviness or discomfort in the upper right abdomen.

When the disease progresses, scarring of the liver becomes severe, and it moves on to cirrhosis, symptoms of decreased liver function may appear from that point on. For example, symptoms such as edema with fluid accumulating in the legs or abdomen, a tendency to bruise easily or increased gum bleeding, itchy skin or jaundice with yellowing of the eyes and skin, and hepatic encephalopathy with clouding of consciousness may appear.

The important message is that "having no symptoms does not mean it is safe." Because symptoms often become clear only after liver damage has progressed considerably, it is more reasonable to judge the condition based on "risk factors" and "test results" rather than symptoms.

Signs

Signs mean "objective signals that a physician confirms through examination or testing." In metabolic dysfunction-associated fatty liver disease, no single specific sign confirms the disease on its own, but several signals related to metabolic health often appear together. The finding commonly accompanying it on physical examination is abdominal obesity. The greater the waist circumference and the more visceral fat, the greater the risk of fatty liver. If dark pigmentation is seen on the skin of the back of the neck or the armpits (a skin change associated with insulin resistance), it suggests the possibility of accompanying metabolic dysfunction.

On blood tests, liver enzymes (aspartate aminotransferase, alanine aminotransferase) may be elevated, but normal levels do not mean there is no fatty liver. Abnormalities such as elevated blood sugar and glycated hemoglobin, elevated triglycerides, and decreased high-density lipoprotein cholesterol are commonly observed together. On imaging, the liver may appear "bright" (suggesting fat deposition on ultrasound), or findings of an enlarged liver may be seen.

Recent research repeatedly emphasizes that when gauging the severity of liver disease, "the degree of fibrosis" is more closely related to prognosis than "the amount of fat." Therefore, when evaluating signs as well, an approach that goes beyond simple fatty liver findings and also assesses the risk of fibrosis is recommended.

Screening

Screening is the process of identifying, among people without symptoms, "groups for whom testing is highly worthwhile." Metabolic dysfunction-associated fatty liver disease is so common that screening the entire population with detailed tests is unrealistic. Instead, it is reasonable to take a stepwise approach centered on high-risk groups. The starting point of screening is identifying risk factors. If there is obesity, abdominal obesity, type 2 diabetes, prediabetes, hypertension, or dyslipidemia, the likelihood of fatty liver is high. Screening with liver enzyme levels alone is incomplete in this situation, because fatty liver and fibrosis can be present even when liver enzymes are normal.

The important purpose in actual screening is to quickly find out "whether scarring of the liver is progressing" rather than "whether there is fatty liver." For this, a blood test-based liver fibrosis risk score (e.g., a score using age, liver enzymes, platelets, etc.) is first calculated to divide people into low, intermediate, and high risk. In this approach, those at low risk undergo lifestyle modification and periodic follow-up, and those at intermediate or high risk undergo additional noninvasive tests. Additional noninvasive tests include ultrasound-based tests that measure liver elasticity (stiffness) and magnetic resonance imaging-based methods.

Recent studies suggest that applying this stepwise screening strategy in high-risk groups such as patients with diabetes makes it possible to find people with advanced fibrosis more efficiently. From the general public's point of view, it can be thought of as an approach that first screens for "whether the liver is hardening" rather than "whether there is fatty liver or not."

Diagnosis

Diagnosis is made along three main axes. First, it is confirmed whether fat has accumulated excessively in the liver. Second, it is confirmed whether metabolic dysfunction is present. Third, other causes (especially viral hepatitis, drugs, certain genetic diseases, etc.) and alcohol factors are evaluated so that the classification is accurate. Abdominal ultrasound is most commonly used to confirm fat accumulation. Ultrasound is readily accessible and relatively inexpensive, but it can miss fat unless there is a great deal of it, and it has limitations in expressing the exact amount of fat numerically. If a more precise assessment is needed, magnetic resonance imaging-based fat quantification is helpful.

Blood tests look at the overall condition through liver enzymes, blood sugar, lipids, inflammatory markers, and so on. However, it is difficult to determine the degree of fatty liver or the stage of inflammation and fibrosis with blood tests alone. Therefore, liver fibrosis risk scores and noninvasive elasticity tests are used together to judge the "level of risk." Liver biopsy is the most precise diagnostic method, but it is invasive, carries a risk of complications, and does not need to be performed in every patient.

An important practical point in the diagnostic process is the assessment of alcohol consumption. The classification becomes accurate only when it is specifically confirmed "how much, how often, and for how long" the person has drunk, rather than simply "I do not drink at all." In addition, having fatty liver does not rule out other liver diseases, so if necessary, hepatitis virus tests and basic tests for causes of liver disease are also performed.

Treatment

The first priority of treatment is lifestyle modification. The interventions whose effectiveness has been most consistently confirmed in metabolic dysfunction-associated fatty liver disease are weight loss, dietary control, and increased physical activity. If body weight is in the overweight or obese range, a certain percentage of weight loss alone can reduce fat in the liver and lower the risk of inflammation and fibrosis. For diet, "what and how much you eat" is the key. It is generally recommended to reduce sugary drinks, excessive refined carbohydrates, and ultra-processed foods, and to eat a balanced diet of fiber-rich vegetables and whole grains, adequate protein, and healthy fats.

Exercise benefits liver health regardless of weight loss. Combining aerobic exercise and strength training improves insulin resistance and can ease the flow of fat into the liver. Drug treatment is often considered not as "a drug only for the liver" but as part of "the process of properly treating the accompanying metabolic diseases." Recent studies report that some drugs used to treat diabetes and drugs that help with weight loss can have positive effects on liver inflammation and fibrosis.

For severe obesity that is difficult to control with lifestyle therapy alone, bariatric surgery can help with steatohepatitis and fibrosis. In addition, if cardiovascular risk is high, "whole-body treatment," such as control of blood pressure, lipids, and blood sugar and treatment of sleep apnea, effectively becomes part of fatty liver treatment.

Prognosis

Prognosis depends more on "how much scarring has accumulated in the liver" than on "how much fat there is." At the stage of simple fat accumulation, the condition is often relatively stable, but when liver inflammation persists and fibrosis progresses, the risk of liver-related complications such as cirrhosis and liver cancer increases. The disease progresses along a spectrum. From the stage in which only fat has accumulated, some move on to steatohepatitis accompanied by inflammation, and in some of those, fibrosis progresses. The rate of progression varies greatly from person to person. Progression can be accelerated by factors such as weight gain, worsening blood sugar, continued drinking, and sleep apnea.

Prognosis outside the liver is also important. Because people with fatty liver tend to have a higher risk of cardiovascular disease, cardiovascular events actually have a greater impact on quality of life and survival in many cases. Therefore, when discussing prognosis, cardiovascular risk must be managed at the same time as the risk of cirrhosis and liver cancer.

Recent studies propose that using noninvasive fibrosis assessment tools to identify high-risk groups early and managing them intensively is the key strategy for improving long-term prognosis. From the general public's point of view, it can be understood that "whether the liver is hardening," rather than "whether liver enzyme levels are slightly high or normal," is the turning point that determines future risk.

Prevention

Prevention follows almost the same direction as treatment. In other words, a lifestyle that protects metabolic health is itself the prevention of fatty liver. The most basic step is managing body weight and waist circumference. When weight increases rapidly or abdominal obesity grows, the likelihood of fat accumulating in the liver rises quickly. In terms of diet, reducing sugary drinks, excessive snacking, and meals centered on refined carbohydrates and switching to a high-fiber diet is beneficial for prevention. Because alcohol can directly damage the liver and worsen body weight and metabolic indicators, it is safer to cut back more strictly the more risk factors you have.

Exercise is a particularly powerful means of prevention. Combining aerobic activity such as regular walking with strength training reduces insulin resistance and maintains muscle mass, which can lower the risk of fatty liver even at the same body weight. If you already have diabetes, hypertension, or dyslipidemia, "treating it well early" is both prevention of fatty liver and prevention of its worsening. In addition, properly evaluating and treating accompanying conditions such as sleep apnea and hypothyroidism improves the metabolic environment and reduces the burden on the liver.

Recent research emphasizes that when fatty liver is discovered at a health checkup, rather than treating it as "a problem of the liver alone," assessing cardiovascular and metabolic risk together and starting lifestyle interventions is the most efficient prevention strategy in the long term.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.